Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L H Brinckerhoff

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|April 6, 2000
Melanoma vaccinesL H Brinckerhoff, L W Thompson, C L Slingluff
Cellular Immunology|September 28, 2000
Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathwaysJ D Lippolis, K S Denis-Mize, L H Brinckerhoff, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 1998
Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2N L Harthun, A M Weaver, L H Brinckerhoff, et al.
International Journal of Cancer|September 25, 1999
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccinesL H Brinckerhoff, V V Kalashnikov, L W Thompson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|April 6, 2000
Melanoma vaccinesL H Brinckerhoff, L W Thompson, C L Slingluff
Cellular Immunology|September 28, 2000
Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathwaysJ D Lippolis, K S Denis-Mize, L H Brinckerhoff, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 1998
Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2N L Harthun, A M Weaver, L H Brinckerhoff, et al.
International Journal of Cancer|September 25, 1999
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccinesL H Brinckerhoff, V V Kalashnikov, L W Thompson, et al.
Pageof 1